3424-43-9

Usage

Uses

Used in Pharmaceutical Synthesis:
ETHYL 6-HYDROXY-2-METHYLPYRIDINE-3-CARBOXYLATE is used as a key intermediate in the synthesis of various pharmaceuticals due to its unique chemical structure and potential biological activities.
Used in Agrochemical Synthesis:
ETHYL 6-HYDROXY-2-METHYLPYRIDINE-3-CARBOXYLATE is also utilized in the synthesis of agrochemicals, contributing to the development of new and effective products for agricultural applications.
Used as a Flavor or Fragrance Ingredient:
The presence of the ester group in ETHYL 6-HYDROXY-2-METHYLPYRIDINE-3-CARBOXYLATE makes it suitable for use as a flavor or fragrance ingredient in various consumer products, such as food, beverages, and cosmetics.
Used in Medicinal Chemistry Research and Development:
The structure of ETHYL 6-HYDROXY-2-METHYLPYRIDINE-3-CARBOXYLATE makes it a promising candidate for further research and development in the field of medicinal chemistry, with potential applications in the discovery of new therapeutic agents.
Used in Anti-Inflammatory Applications:
ETHYL 6-HYDROXY-2-METHYLPYRIDINE-3-CARBOXYLATE is used as an anti-inflammatory agent, potentially providing relief from inflammation and related symptoms in various conditions.
Used in Antioxidant Applications:
ETHYL 6-HYDROXY-2-METHYLPYRIDINE-3-CARBOXYLATE is also used as an antioxidant, helping to protect cells from oxidative damage and potentially reducing the risk of various diseases associated with oxidative stress.
Used in the Flavor and Fragrance Industry:
ETHYL 6-HYDROXY-2-METHYLPYRIDINE-3-CARBOXYLATE is used as a flavor or fragrance ingredient in the flavor and fragrance industry, contributing to the creation of unique and appealing scents and tastes in various products.

InChI:InChI=1/C9H11NO3/c1-3-13-9(12)7-4-5-8(11)10-6(7)2/h4-5H,3H2,1-2H3,(H,10,11)

Upstream product

• 4027-39-8 2-methyl-6-oxo-1,4,5,6-tetrahydro-pyridine-3-carboxylic acid ethyl ester 
• 1039037-16-5 5-ethyl 1-methyl 4-(1-amino-ethylidene)-pent-2-enedioate 
• 626-34-6 ethyl 3-aminobut-2-enoate 
• 53256-25-0 (2E,4Z)-5-ethyl 1-methyl 4-(1-aminoethylidene)pent-2-enedioate 
• 141-97-9 ethyl acetoacetate 
• 68-12-2 N,N-dimethyl-formamide 
• 626-34-6 ethyl aminocrotonate 
• 141-52-6 sodium ethanolate 
• 95387-37-4 (Z)-5-(2-carbamoylvinyl)-1,3,6-trimethyluracil 
• 95387-40-9 (E)-5-(2-carbamoylvinyl)-1,3,6-trimethyluracil 
• 546-67-8 lead(IV) tetraacetate 
• 6296-99-7 diethyl aminomethylenemalonate 
• 100643-08-1 (Z)-ethyl 2-(aminomethylene)-3-oxobutanoate 
• 1432-45-7 N-acetyl acrylamide 

Downstream Products

• 41598-57-6 ethyl 2-chloro-5-oxo-6,7-dihydro-5H-cyclopenta[b]pyridine-6-carboxylate 
• 1196154-17-2 2?methoxy?6,7?dihydro?5H?cyclopenta[b]pyridine?5?one 
• 173261-76-2 ethyl 6-methoxy-2-methylnicotinate 
• 1174665-76-9 5-iodo-2-methyl-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid ethyl ester 
• 1359669-60-5 C₂₃H₂₁NO₂ 
• 1359669-62-7 diethyl {2-[(2',6'-dimethylbiphenyl-3-yl)methoxy]-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl}malonate 
• 1359668-78-2 2-[(2',6'-dimethylbiphenyl-3-yl)methoxy]-6,7-dihydro-5H-cyclopenta[b]pyridin-5-ol 
• 1359668-80-6 {2-[(2',6'-dimethylbiphenyl-3-yl)methoxy]-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl}acetic acid 
• 1227515-71-0 6-methoxy-2-methylnicotinic acid 
• 1430058-83-5 C₂₅H₂₉N₅O₃ 
• 1430058-81-3 C₂₁H₂₄BrN₃O₃ 
• 1430057-55-8 6-[(1S)-2-amino-1-benzylethyl]-2-(1-methyl-1H-pyrazol-5-yl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one 
• 1430057-53-6 6-[(1S)-2-amino-1-(3-fluorobenzyl)ethyl]-2-(4-chloro-1-methyl-1H-pyrazol-5-yl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one 
• 1430058-79-9 2-[(2S)-2-[2-(4-chloro-1-methyl-1H-pyrazol-5-yl)-5-oxo-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-3-(3-fluorophenyl)propyl]-1H-isoindole-1,3(2H)-dione 

Relevant academic research and scientific papers

HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF

The present invention relates to a histone acetyltransferase (HAT) inhibitor. Provided are a compound represented by general formula I, a pharmaceutically acceptable salt, a stereoisomer, an enantiomer, a diastereomer, an atropisomer, a racemate, a polymorph, a solvate or an isotope-labeled compound (including deuterium substitution) thereof, a preparation method therefor, a pharmaceutical composition comprising the same, and use thereof in the treatment of various HAT-related diseases or conditions.

Preparation method of 2-methoxy-6, 7-dihydro-5H-cyclopenta [b] pyridine-5-one

The invention relates to a preparation method of 2-methoxy-6,7-dihydro-5H-cyclopenta[b]pyridine-5-one. According to the preparation method, ethyl acetoacetate is used as a starting raw material, and anovel target product 2-methoxy-6, 7-dihydro-5H-cyclopenta[b]pyridine-5-one is prepared through nine steps of reactions including dehydration, addition, cyclization, chlorination, bromination, substitution, cyclization again, decarboxylation and etherification. The preparation method of the novel target product is simple and efficient. The purity of the novel target product prepared by the methoddisclosed by the invention reaches over 99.0%.

Ru-Catalyzed Regioselective Cascade Annulation of Acrylamides with 2-Alkynoates for the Synthesis of Various 6-Oxo Nicotinic Acid Esters

Ru-catalyzed regioselective cascade annulation of acrylamides with 2-alkynoates via aza-Michael/C-H activation sequence for the synthesis of various 6-oxo nicotinic acid esters is described. The regioselectivity of the protocol has been confirmed by performing silver mediated protodecarboxylation of the corresponding 6-oxo nicotinic acid to furnish 2-pyridone. The developed protocol is copper or silver salt-free and uses inexpensive, safe, and environmentally benign peroxide-based "oxone" as the sole oxidant. A redox-neutral version of the protocol is also demonstrated.

Novel nicotinamide analog as inhibitor of nicotinamide N-methyltransferase

Nicotinamide N-methyltransferase (NNMT) has been linked to obesity and diabetes. We have identified a novel nicotinamide (NA) analog, compound 12 that inhibited NNMT enzymatic activity and reduced the formation of 1-methyl-nicotinamide (MNA), the primary metabolite of NA by ～80% at 2 h when dosed in mice orally at 50 mg/kg.

SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE

Compounds having a structure of Formula (IX) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1----Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.

ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS

The present invention provides isoindolinone and pyrrolopyridinone derivatives, as well as their compositions and methods of use, that inhibit the activity of the serine/threonine kinase, Akt, and are useful in the treatment of diseases related to the act

Identification of fused-ring alkanoic acids with improved pharmacokinetic profiles that Act as G protein-coupled receptor 40/free fatty acid receptor 1 agonists

The G protein-coupled receptor 40 (GPR40)/free fatty acid receptor 1 (FFA1) has emerged as an attractive target for a novel insulin secretagogue with glucose dependency. We previously identified phenylpropanoic acid derivative 1 (3-{4-[(2′,6′-dimethylbiphenyl-3-yl)methoxy]-2-fluorophenyl} propanoic acid) as a potent and orally available GPR40/FFA1 agonist; however, 1 exhibited high clearance and low oral bioavailability, which was likely due to its susceptibility to β-oxidation at the phenylpropanoic acid moiety. To identify long-acting compounds, we attempted to block the metabolically labile sites at the phenylpropanoic acid moiety by introducing a fused-ring structure. Various fused-ring alkanoic acids with potent GPR40/FFA1 activities and good PK profiles were produced. Further optimizations of the lipophilic portion and the acidic moiety led to the discovery of dihydrobenzofuran derivative 53 ((6-{[4′-(2-ethoxyethoxy)-2′,6′-dimethylbiphenyl-3-yl]methoxy} -2,3-dihydro-1-benzofuran-3-yl)acetic acid), which acted as a GPR40/FFA1 agonist with in vivo efficacy during an oral glucose tolerance test (OGTT) in rats with impaired glucose tolerance.

Small molecule antagonist of leukocyte function associated antigen-1 (LFA-1): Structure-activity relationships leading to the identification of 6-((5 S,9 R)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7- triazaspiro[4.4]nonan-7-yl)nico

Leukocyte function-associated antigen-1 (LFA-1), also known as CD11a/CD18 or αLβ2, belongs to the β2 integrin subfamily and is constitutively expressed on all leukocytes. The major ligands of LFA-1 include three intercellu

INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY

Compounds of formula (I) have checkpoint kinase 1 (CHK1 ) inhibitory activity: wherein R1, R2, R5 and R6 are independently selected from hydrogen, hydroxy, methyl, trifluoromethyl, hydroxymethyl, methoxy, triflu

NEW PYRIDINE ANALOGUES VIII 518

The present invention relates to certain new pyridin analogues of Formula ( I ) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.